Horizon Pharma to Buy Raptor Pharmaceutical for $800 Million

San Diego – September 15, 2016 – Cooley advised Horizon Pharma on its agreement to acquire Raptor Pharmaceutical for approximately $800 million. The transaction is expected to close in the fourth quarter.

“The proposed acquisition of Raptor furthers our commitment to helping people with rare diseases and is a significant step in advancing our strategy to expand our rare disease business,” said Timothy P Walbert, chairman, president and CEO of Horizon.

Horizon, headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases.

Cooley has a longstanding relationship with Horizon, including taking the company public in 2011. In 2015, Cooley advised Horizon on its largest acquisition to date – the acquisition of Hyperion Therapeutics for $1.1 billion, as well as its acquisition of Crealta for $510 million. Cooley helped Horizon fund this transaction through several equity and debt financings.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Press Coverage:

"More Rare Disease Deal Making to Follow Horizon's Raptor Deal," The Deal

"Horizon Buys Rare-Disease Company Raptor for $800 Million," The Washington Post

"Horizon Pharma Swoops in on Raptor," The Deal

"HZNP, RPTP: Horizon Pharma PLC Stock Jumps on $800 Million Raptor Pharmaceutical Corp. Buy," InvestorPlace

"Horizon Pharma Buys Rare-Disease Company Raptor for $800 Million," Crain’s Chicago Business

"Horizon Buys Rare-Disease Company Raptor for $800 Million," Bloomberg

"Horizon Pharma to Buy Raptor Pharma for $800 Mln," Reuters

"New ‘Horizon’ for Raptor in $800M Cash Deal," BioWorld

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.